PEGCETACOPLAN (APL-2)

DRUG3 trials

Sponsors

Apellis Pharmaceuticals, Inc.

Conditions

Amyotrophic Lateral SclerosisGeographic AtrophyGeographic Atrophy Secondary to Age-related Macular DegenerationMotor Neuron Disease

Phase 1

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

CompletedNCT03777332

Apellis Pharmaceuticals, Inc.Geographic Atrophy

Start: 2018-11-05End: 2021-04-01Updated: 2021-11-10

Phase 2

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

TerminatedNCT04579666

Apellis Pharmaceuticals, Inc.Amyotrophic Lateral Sclerosis, Motor Neuron Disease

Start: 2020-09-30End: 2023-07-13Updated: 2025-04-24

Phase 3

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

CompletedNCT04770545

Apellis Pharmaceuticals, Inc.Geographic Atrophy Secondary to Age-related Macular Degeneration

Start: 2021-03-04End: 2025-09-05Updated: 2026-06-18

Related Papers

Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE.

2025-04-233 citations

Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham

CPT Pharmacometrics & Systems Pharmacology2024-11-052 citations

MERIDIAN: A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with amyotrophic lateral sclerosis

2021-01-01